One of the first hints towards a clinically relevant crosstalk between p38 and GR signaling was the study by Irusen et al. [31], which demonstrated that the p38 inhibitor SB203580 potentially reverses the GC insensitivity in patients with severe asthma. The gene discussed is MAPK14; the disease is asthma.